Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Finance Watch: Biopharma IPOs Defy Broader Stock Performance Trends

Executive Summary

Public Company Edition: With returns for newly public biopharma companies rising, seven more jumped in line to go public in the US between the beginning of February and early March, while two drug developers launched IPOs in the EU. Meanwhile, already public companies keep raising gobs of cash.


Related Content

Incentives, Novel Tech Seen Driving Multiple Korean IPOs In 2018
Closer To Home: Hong Kong Takes On Nasdaq For China Biotech IPOs
Acacia's Euronext Listing To Help Target Unmet US PONV Market
IPO Update: Seven In January As Big Returns, Solid's Slip-Up Contribute To Bubble Concerns
Allergan Relying On 'Six Stars' And Other R&D Programs To Blunt Restasis Blow
Finance Watch: A Bountiful November Harvest For Venture-Backed Biopharma
Antibiotic Pipeline Profile: Targeting Delivery To Infection Site
Video Interview: TLC Delivers Sustained Release And Improved Tissue Targeting
Takeda seeks 'big data' analytics for rare disease drug discovery
Biotech VC dips in 3Q, but 2014 on track to beat 2013


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts